Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patent filing numbers raise more concerns over antibiotic innovation

This article was originally published in Scrip

Executive Summary

New figures detailing the number of patent filings in the antibiotic space suggests that the issue of resistance is still not being addressed adequately. The fact that the antibiotic industry is not innovating at the same pace as other areas of the pharmaceutical industry has been highlighted through an analysis of filings over the past ten years by IP lawyers at Marks & Clerk. In its latest report, From rare to routine – medicines for rare diseases, vaccines and antibiotics, the firm emphasizes why it believes that the antibiotics market is "at risk of losing another decade to inadequate levels of research and innovation."

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC029002

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel